Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3713372 in MTAP-deleted Solid Tumors
NCT06914128Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Mar 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of BAY 3713372 in solid tumor, non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and 1 more (9 cohorts), sponsored by Bayer. Primary endpoints: Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events and 6 more. Started Mar 2025; status: recruiting.
02
Drugs
BAY 3713372
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06914128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914128.